ARDX Quote, Financials, Valuation and Earnings

Esperion Therapeutics has a net margin of 4% compared to Ardelyx's net margin of -30.85%. Ardelyx's return on equity of -24.57% beat Esperion Therapeutics's return on equity of --.

Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 141.03%. On the other hand Esperion Therapeutics has an analysts' consensus of $6.63 which suggests that it could grow by 550.12%. Given that Esperion Therapeutics has higher upside potential than Ardelyx, analysts believe Esperion Therapeutics is more attractive than Ardelyx.

Ardelyx has a beta of 0.815, which suggesting that the stock is 18.53% less volatile than S&P 500. In comparison Esperion Therapeutics has a beta of 0.863, suggesting its less volatile than the S&P 500 by 13.744%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Esperion Therapeutics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are larger than Esperion Therapeutics quarterly revenues of $69.1M. Ardelyx's net income of $4.6M is higher than Esperion Therapeutics's net income of -$21.3M. Notably, Ardelyx's price-to-earnings ratio is -- while Esperion Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.14x versus 0.59x for Esperion Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of 4% compared to Ardelyx's net margin of -225.53%. Ardelyx's return on equity of -24.57% beat Insmed's return on equity of -41989.34%.

Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 141.03%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 39.68%. Given that Ardelyx has higher upside potential than Insmed, analysts believe Ardelyx is more attractive than Insmed.

Ardelyx has a beta of 0.815, which suggesting that the stock is 18.53% less volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are larger than Insmed quarterly revenues of $104.4M. Ardelyx's net income of $4.6M is higher than Insmed's net income of -$235.5M. Notably, Ardelyx's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.14x versus 30.92x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Repligen has a net margin of 4% compared to Ardelyx's net margin of -20.22%. Ardelyx's return on equity of -24.57% beat Repligen's return on equity of -1.29%.

Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 141.03%. On the other hand Repligen has an analysts' consensus of $190.27 which suggests that it could grow by 54.87%. Given that Ardelyx has higher upside potential than Repligen, analysts believe Ardelyx is more attractive than Repligen.

Ardelyx has a beta of 0.815, which suggesting that the stock is 18.53% less volatile than S&P 500. In comparison Repligen has a beta of 1.266, suggesting its more volatile than the S&P 500 by 26.606%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. Repligen pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are smaller than Repligen quarterly revenues of $167.5M. Ardelyx's net income of $4.6M is higher than Repligen's net income of -$33.9M. Notably, Ardelyx's price-to-earnings ratio is -- while Repligen's PE ratio is 633.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.14x versus 10.89x for Repligen. Usually stocks with elevated PS ratios are considered overvalued.

United Therapeutics has a net margin of 4% compared to Ardelyx's net margin of 40.94%. Ardelyx's return on equity of -24.57% beat United Therapeutics's return on equity of 20.21%.

Ardelyx has a consensus price target of $10.75, signalling upside risk potential of 141.03%. On the other hand United Therapeutics has an analysts' consensus of $400.48 which suggests that it could grow by 42.44%. Given that Ardelyx has higher upside potential than United Therapeutics, analysts believe Ardelyx is more attractive than United Therapeutics.

Ardelyx has a beta of 0.815, which suggesting that the stock is 18.53% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.632, suggesting its less volatile than the S&P 500 by 36.833%.

Ardelyx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ardelyx pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

Ardelyx quarterly revenues are $116.1M, which are smaller than United Therapeutics quarterly revenues of $735.9M. Ardelyx's net income of $4.6M is lower than United Therapeutics's net income of $301.3M. Notably, Ardelyx's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 11.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ardelyx is 3.14x versus 4.74x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.